Marksans Pharma Consolidated March 2023 Net Sales at Rs 485.98 crore, up 16.25% Y-o-Y
30-05-2023
MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Change in Directorate
Change in Independent Director.30-05-2023
MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release -- Q4FY23 and FY23 Financial Results30-05-2023
MARKSANS PHARMA LTD. - 524404 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation Q4FY23 and FY2330-05-2023
MARKSANS PHARMA LTD. - 524404 - Board Meeting Outcome for Outcome Of Board Meeting
Outcome of Board Meeting30-05-2023
MARKSANS PHARMA LTD. - 524404 - Audited Financial Results For The Quarter And Financial Year Ended 31St March, 2023 And Auditors Report Thereon.
Attached herewith Audited Financial Results for the quarter and financial year ended 31st March, 2023 and Auditors Report thereon.30-05-2023
MARKSANS PHARMA LTD. - 524404 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Pursuant to Regulation 24A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with relevant Circulars issued by the Securities and Exchange Board of India from time to time, please find enclosed the Annual Secretarial Compliance Report for the financial year ended 31st March, 2023 issued by Mr. Jinesh Dedhia of Jinesh Dedhia & Associates, Practicing Company Secretaries.29-05-2023
MARKSANS PHARMA LTD. - 524404 - Notice Of Record Date
Company has fixed 7th June, 2023 for payment of dividend, if declared at the Board Meeting scheduled to be held on 30th May, 2023 for financial year 2022-23.24-05-2023